Medimmune starts phase I clinical trial to investigate an antibody developed under a collaboration with Humabs BioMed for the treatment of influenza A. The novel antibody developed through Humabs’ Cellclone technology will be investigated a trial being conducted by MedImmune, the global biologics research and development arm of AstraZeneca.
The investigational antibody, which has broad influenza-neutralizing properties, was isolated by Humabs from human memory B cells and further optimized for higher potency by MedImmune. The resulting antibody, MEDI8852, is exclusively licensed to MedImmune. The Phase I trial is designed to evaluate the safety and pharmacokinetics of MEDI8852 in healthy adults.
“Our strong, ongoing partnership and collaborations with Humabs reflect our commitment to seeking out innovative new science and technologies, both within and outside our organization, that can help expedite and advance the development of new medicines for the prevention and treatment of challenging infectious diseases,” said Dr. JoAnn Suzich, vice president of infectious disease research and development at MedImmune.
MEDI8852 binds to a novel site in the hemagglutinin stem region that is shared in viruses from all 18 Influenza A subtypes.